{"id":"withdrawal-of-therapy","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL3770173","moleculeType":"Small molecule","molecularWeight":"440.32"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a clinical intervention rather than a drug itself, used in research or clinical practice to evaluate the natural history of a disease or the durability of treatment effect after cessation. It may be employed as a control arm in trials or as a therapeutic strategy to determine if continued medication is necessary.","oneSentence":"Withdrawal of therapy involves discontinuing an active pharmaceutical treatment to assess disease progression or allow natural resolution.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:16:10.623Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT07483983","phase":"PHASE2","title":"Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/Resistance","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2026-03","conditions":"Metastatic/Locally Advanced Non-Small-Cell Lung Cancer, Metastatic/Locally Pancreatic Ductal Adenocarcinoma","enrollment":60},{"nctId":"NCT06902246","phase":"PHASE2","title":"Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"University of Miami","startDate":"2026-05-01","conditions":"Unresectable Hepatocellular Carcinoma, Hepatocellular Carcinoma","enrollment":30},{"nctId":"NCT05711615","phase":"PHASE1","title":"Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-02-06","conditions":"Metastatic Dedifferentiated Liposarcoma, Metastatic Leiomyosarcoma, Metastatic Myxofibrosarcoma","enrollment":30},{"nctId":"NCT07172919","phase":"PHASE2","title":"A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation","status":"RECRUITING","sponsor":"Amgen","startDate":"2026-01-02","conditions":"Advanced Solid Tumors","enrollment":14},{"nctId":"NCT05226117","phase":"PHASE2","title":"Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder Cancer","status":"COMPLETED","sponsor":"IRCCS San Raffaele","startDate":"2022-03-23","conditions":"Urothelial Carcinoma","enrollment":44},{"nctId":"NCT07296094","phase":"PHASE2","title":"Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder","status":"NOT_YET_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2026-05-01","conditions":"Alcohol Use Disorder","enrollment":36},{"nctId":"NCT05063565","phase":"PHASE2","title":"TheraSphere With Durvalumab and Tremelimumab for HCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boston Scientific Corporation","startDate":"2023-11-03","conditions":"Hepatocellular Carcinoma","enrollment":100},{"nctId":"NCT07494448","phase":"PHASE1, PHASE2","title":"Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"MedSIR","startDate":"2026-07-01","conditions":"HER 2 Positive Advanced Breast Cancer, Breast Cancer","enrollment":24},{"nctId":"NCT04660344","phase":"PHASE3","title":"A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-05-03","conditions":"Muscle-invasive Bladder Cancer","enrollment":761},{"nctId":"NCT03410992","phase":"PHASE3","title":"A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2018-02-05","conditions":"Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis, Psoriatic Arthritis","enrollment":435},{"nctId":"NCT05068440","phase":"PHASE2","title":"Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib","status":"COMPLETED","sponsor":"BeiGene","startDate":"2021-08-11","conditions":"Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma","enrollment":65},{"nctId":"NCT04670679","phase":"PHASE1","title":"A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Erasca, Inc.","startDate":"2020-12-15","conditions":"Advanced or Metastatic Solid Tumors","enrollment":90},{"nctId":"NCT07491913","phase":"NA","title":"Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission","status":"RECRUITING","sponsor":"Marmara University","startDate":"2025-06-15","conditions":"Takayasu Arteritis","enrollment":40},{"nctId":"NCT04221204","phase":"PHASE1","title":"A Monotherapy in Subjects With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"3D Medicines (Beijing) Co., Ltd.","startDate":"2019-09-01","conditions":"Solid Tumor, Adult","enrollment":42},{"nctId":"NCT06863272","phase":"PHASE1, PHASE2","title":"A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-07-03","conditions":"Castration-Resistant Prostatic Cancer, Metastasis","enrollment":360},{"nctId":"NCT06441604","phase":"PHASE2","title":"Extended-release Buprenorphine as a Novel Low-dose Induction Strategy","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2025-10-27","conditions":"Opioid Use Disorder","enrollment":30},{"nctId":"NCT07123883","phase":"NA","title":"Dry Needling for Temporomandibular Disorder","status":"COMPLETED","sponsor":"Atlas University","startDate":"2025-07-28","conditions":"TMD/Orofacial Pain, Muscle Spasm","enrollment":40},{"nctId":"NCT07489352","phase":"NA","title":"N-of-1 Trial to Promote Beta-Blocker Titration in Heart Failure","status":"NOT_YET_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2026-05-05","conditions":"Heart Failure, Beta-blocker, Older Adults","enrollment":50},{"nctId":"NCT07235293","phase":"PHASE2","title":"A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.","status":"RECRUITING","sponsor":"Kahr Bio Australia Pty Ltd","startDate":"2026-01-16","conditions":"Colorectal Cancer","enrollment":90},{"nctId":"NCT07221786","phase":"NA","title":"Preoperative Opioid Tapering Before Spine Surgery","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2025-12-01","conditions":"Opioid Consumption, Postoperative, Pain After Surgery, Opioid Dependency","enrollment":45},{"nctId":"NCT07489547","phase":"PHASE2, PHASE3","title":"Medication Withdrawal in Stable HF With Improved LVEF","status":"RECRUITING","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2025-03-01","conditions":"Heart Failure","enrollment":90},{"nctId":"NCT07300514","phase":"PHASE3","title":"Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-03-30","conditions":"Maintenance Treatment of Peripheral T-cell Lymphoma","enrollment":136},{"nctId":"NCT04008797","phase":"PHASE1, PHASE2","title":"A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eisai Inc.","startDate":"2019-07-11","conditions":"Endometrial Neoplasms, Neoplasms, Carcinoma, Hepatocellular","enrollment":301},{"nctId":"NCT01581554","phase":"","title":"Withdrawal of Therapy After Long-Term Antiviral Treatment for Chronic Hepatitis B","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2011-05-18","conditions":"Chronic Hepatitis B e Antigen Positive, Chronic Hepatitis B e Antigen Negative","enrollment":15},{"nctId":"NCT06667076","phase":"PHASE2","title":"A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-12-16","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":480},{"nctId":"NCT05030038","phase":"","title":"Oral Aromatase Inhibitors Modify the Gut Microbiome","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2022-03-29","conditions":"Breast Cancer","enrollment":25},{"nctId":"NCT07487519","phase":"PHASE2","title":"Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Breast Cancer.","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2026-04-25","conditions":"Breast Cancer (Triple Negative Breast Cancer (TNBC))","enrollment":180},{"nctId":"NCT07488884","phase":"PHASE1","title":"Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2026-03-01","conditions":"Pancreatic Cancer Resectable, Pancreatic Cancer","enrollment":30},{"nctId":"NCT06399653","phase":"NA","title":"Non-invasive Vagal Nerve Stimulation as Novel Treatment to Improve Functional Outcomes in Veterans With Alcohol Use Disorder","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2025-01-01","conditions":"Alcohol Use Disorder","enrollment":80},{"nctId":"NCT07488572","phase":"PHASE2","title":"Safety and Efficacy of Yiwoxidan Anti (AK112) Monotherapy in Patients With Metastatic Renal Clear Cell Carcinoma Who Are Intolerant to TKI Treatment: a Prospective, Single Arm, Phase II Clinical Study","status":"ENROLLING_BY_INVITATION","sponsor":"Sun Yat-sen University","startDate":"2025-11-01","conditions":"Renal Cell Carcinoma (RCC), Metastatic Clear Cell Renal Cell Carcinoma","enrollment":60},{"nctId":"NCT05595577","phase":"NA","title":"Improving Exercise Capacity With a Tailored Physical Activity Intervention","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2023-03-01","conditions":"Non Hodgkin Lymphoma, Heart; Functional Disturbance, Hodgkin Lymphoma","enrollment":110},{"nctId":"NCT07484217","phase":"PHASE3","title":"Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol","status":"RECRUITING","sponsor":"Axsome Therapeutics, Inc.","startDate":"2026-02-23","conditions":"Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms","enrollment":508},{"nctId":"NCT07363720","phase":"PHASE3","title":"A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy","status":"RECRUITING","sponsor":"Takeda","startDate":"2026-01-29","conditions":"Narcolepsy Type 1 (NT1), Narcolepsy With Cataplexy","enrollment":88},{"nctId":"NCT06842498","phase":"PHASE2","title":"A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)","status":"RECRUITING","sponsor":"Kyntra Bio","startDate":"2026-02-22","conditions":"Metastatic Castration-Resistant Prostate Cancer","enrollment":75},{"nctId":"NCT07294508","phase":"PHASE2, PHASE3","title":"A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2026-02-27","conditions":"HER2 + Breast Cancer","enrollment":706},{"nctId":"NCT05029141","phase":"PHASE2","title":"New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2021-09-01","conditions":"Acute Myeloid Leukemia, Refractory Acute Leukemia, Relapsed Adult AML","enrollment":21},{"nctId":"NCT07482059","phase":"PHASE1, PHASE2","title":"A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2026-02","conditions":"Unresectable Hepatocellular Carcinoma","enrollment":33},{"nctId":"NCT04083976","phase":"PHASE2","title":"A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-11-20","conditions":"Advanced Solid Tumor","enrollment":316},{"nctId":"NCT03491683","phase":"PHASE1, PHASE2","title":"INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Inovio Pharmaceuticals","startDate":"2018-05-31","conditions":"Glioblastoma","enrollment":52},{"nctId":"NCT03390504","phase":"PHASE3","title":"A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2018-03-23","conditions":"Urothelial Cancer","enrollment":629},{"nctId":"NCT07483970","phase":"PHASE1","title":"A Phase I/II Study of JL19001 Injection Alone or in Combination With BCG in Subjects With High Risk Non-Muscle Invasive Bladder Cancer.","status":"NOT_YET_RECRUITING","sponsor":"Jecho Biopharmaceuticals Co., Ltd.","startDate":"2026-03-30","conditions":"High Risk Non-muscle Invasive Bladder Cancer","enrollment":18},{"nctId":"NCT07405164","phase":"PHASE3","title":"Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-03-23","conditions":"Von Hippel-Lindau Disease, Carcinoma, Renal Cell","enrollment":450},{"nctId":"NCT03596645","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2018-10-29","conditions":"Colitis, Ulcerative","enrollment":84},{"nctId":"NCT03793361","phase":"PHASE2","title":"Phase II Study of Regorafenib as Maintenance Therapy","status":"COMPLETED","sponsor":"Centre Oscar Lambret","startDate":"2019-05-15","conditions":"Metastatic Soft Tissue Sarcoma","enrollment":127},{"nctId":"NCT07205822","phase":"PHASE3","title":"A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-10-30","conditions":"Breast Cancer","enrollment":100},{"nctId":"NCT07454642","phase":"PHASE1","title":"AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors","status":"RECRUITING","sponsor":"Avacta Life Sciences Ltd","startDate":"2026-03","conditions":"Vulvar Adenocarcinoma, PDAC - Pancreatic Ductal Adenocarcinoma, Gastric Adenocarcinoma","enrollment":144},{"nctId":"NCT07270770","phase":"PHASE1","title":"BY002 IIT Study in R/R Acute Leukemia","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2026-03-15","conditions":"Acute Leukemia, KMT2A Rearrangements or NPM1 Mutations Acute Leukemia","enrollment":18},{"nctId":"NCT03301220","phase":"PHASE3","title":"A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2017-11-07","conditions":"Smoldering Multiple Myeloma","enrollment":390},{"nctId":"NCT07052162","phase":"PHASE4","title":"Investigating the Pharmacokinetics of Tafenoquine in Healthy Papua New Guinean Children","status":"RECRUITING","sponsor":"Curtin University","startDate":"2025-10-20","conditions":"Pharmacokinetics of Tafenoquine","enrollment":30},{"nctId":"NCT05889494","phase":"NA","title":"Autologous Whole Blood Management for Transfusion Reduction in Adult Cardiac Surgery Patients","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2025-03-24","conditions":"Postoperative Hemorrhage, Postoperative Anemia, Postoperative Blood Loss","enrollment":64},{"nctId":"NCT05100862","phase":"PHASE3","title":"A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma","status":"RECRUITING","sponsor":"BeiGene","startDate":"2022-03-10","conditions":"Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma","enrollment":780},{"nctId":"NCT02838420","phase":"PHASE3","title":"A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2016-08-03","conditions":"Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer","enrollment":187},{"nctId":"NCT07221396","phase":"NA","title":"LDART for Stimulant Use Disorder","status":"NOT_YET_RECRUITING","sponsor":"Yale University","startDate":"2026-04-01","conditions":"Stimulant Use Disorder, Cocaine Use Disorder, Methamphetamine Use Disorder","enrollment":80},{"nctId":"NCT04077463","phase":"PHASE1","title":"A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-09-04","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":701},{"nctId":"NCT05694715","phase":"PHASE1","title":"Combination Therapy in Cancers With Mutations in DNA Repair Genes","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2023-05-23","conditions":"Metastatic Solid Tumor, BRCA1 Mutation, BRCA2 Mutation","enrollment":24},{"nctId":"NCT06859424","phase":"PHASE2","title":"A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2025-07-25","conditions":"AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category)","enrollment":358},{"nctId":"NCT06531876","phase":"","title":"Efficacy of the Dreem 3S Ambulatory Sleep Monitoring Device for the Evaluation of Narcolepsy","status":"COMPLETED","sponsor":"Beacon Biosignals","startDate":"2024-07-01","conditions":"Narcolepsy Type 1, Hypersomnia, Sleep Disorder","enrollment":78},{"nctId":"NCT07474064","phase":"PHASE2","title":"Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC","status":"NOT_YET_RECRUITING","sponsor":"chenxu","startDate":"2026-03-26","conditions":"Muscle Invasive Bladder Cancer (MIBC)","enrollment":146},{"nctId":"NCT04531917","phase":"NA","title":"The Effect of Pain Neuroscience Education and Behavioural Graded Activity on Chronic Pain in Breast Cancer Survivors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2020-10-12","conditions":"Breast Neoplasms, Survivors, Chronic Pain","enrollment":122},{"nctId":"NCT05081999","phase":"PHASE4","title":"De-Adoption of Beta-Blockers in Patients With Stable Ischemic Heart Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Alberta","startDate":"2023-01-30","conditions":"Stable Ischemic Heart Disease, Coronary Artery Disease, Beta-blocker Therapy","enrollment":59},{"nctId":"NCT05309655","phase":"NA","title":"Cardiac Outcomes With Near-Complete Estrogen Deprivation","status":"RECRUITING","sponsor":"Duke University","startDate":"2022-09-02","conditions":"Breast Cancer, Triple Negative Breast Cancer, Cardiovascular Complications","enrollment":90},{"nctId":"NCT06894771","phase":"PHASE1","title":"A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-04-23","conditions":"Malignant Neoplasm","enrollment":5},{"nctId":"NCT07246902","phase":"","title":"Mobilization and Outcomes After Venous Closure","status":"RECRUITING","sponsor":"Cordis US Corp.","startDate":"2025-11-24","conditions":"Venous Vascular Closure, Electrophysiology Study","enrollment":300},{"nctId":"NCT06095115","phase":"PHASE3","title":"A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2023-10-12","conditions":"Plaque Psoriasis","enrollment":684},{"nctId":"NCT03643510","phase":"PHASE2","title":"Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-08-21","conditions":"Adenocarcinoma of Endometrium","enrollment":28},{"nctId":"NCT03911466","phase":"","title":"Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study","status":"COMPLETED","sponsor":"T. John Winhusen, PhD","startDate":"2020-07-21","conditions":"Opioid-Related Disorders, Drug Addiction, Pregnancy Related","enrollment":97},{"nctId":"NCT03911739","phase":"","title":"Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-study","status":"COMPLETED","sponsor":"T. John Winhusen, PhD","startDate":"2021-06-14","conditions":"Opioid-Related Disorders, Drug Addiction, Pregnancy Related","enrollment":71},{"nctId":"NCT05230810","phase":"PHASE1, PHASE2","title":"Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Criterium, Inc.","startDate":"2022-08-25","conditions":"HER2-positive Metastatic Breast Cancer","enrollment":40},{"nctId":"NCT07472478","phase":"PHASE2","title":"Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12C-Mutant NSCLC (GIVEN Study)","status":"NOT_YET_RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2026-03-15","conditions":"Lung Cancer (NSCLC), KRAS G12C Lung Cancer","enrollment":32},{"nctId":"NCT07475728","phase":"","title":"EMS-Initiated Buprenorphine","status":"NOT_YET_RECRUITING","sponsor":"Yale University","startDate":"2026-03","conditions":"Opioid Use Disorder","enrollment":495},{"nctId":"NCT04108208","phase":"PHASE4","title":"A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-12-17","conditions":"Prostatic Neoplasms","enrollment":75},{"nctId":"NCT04181827","phase":"PHASE3","title":"A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2020-06-12","conditions":"Multiple Myeloma","enrollment":419},{"nctId":"NCT06741969","phase":"PHASE3","title":"Nipocalimab in Moderate to Severe Sjogren's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-12-04","conditions":"Sjogrens Syndrome","enrollment":655},{"nctId":"NCT07320586","phase":"PHASE2","title":"Carilizumab and Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer","status":"RECRUITING","sponsor":"Shandong Tumor Hospital","startDate":"2021-03-01","conditions":"Gastric Cancer, Second-line Therapy","enrollment":40},{"nctId":"NCT05853367","phase":"PHASE1","title":"Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-07-06","conditions":"Metastatic Solid Tumors, Advanced Solid Tumors","enrollment":178},{"nctId":"NCT07463235","phase":"PHASE3","title":"Safety and Potency of a High Cabergoline Dosage in Microprolactinomas","status":"RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2026-03-04","conditions":"Prolactinoma, Prolactin Excess","enrollment":70},{"nctId":"NCT05179876","phase":"PHASE3","title":"A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option","status":"RECRUITING","sponsor":"Actelion","startDate":"2022-05-04","conditions":"Hypertension, Pulmonary","enrollment":280},{"nctId":"NCT05862012","phase":"PHASE1","title":"Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)","status":"RECRUITING","sponsor":"Ichnos Sciences SA","startDate":"2023-11-01","conditions":"Relapsed/Refractory Multiple Myeloma","enrollment":200},{"nctId":"NCT07459608","phase":"PHASE2","title":"Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Indolent Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2026-03-10","conditions":"Indolent Lymphoma, WM, MZL","enrollment":75},{"nctId":"NCT06008288","phase":"PHASE2","title":"A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.","status":"RECRUITING","sponsor":"Allist Pharmaceuticals, Inc.","startDate":"2023-10-27","conditions":"KRAS P.G12C, Pancreatic Cancer, Solid Tumor","enrollment":88},{"nctId":"NCT05567185","phase":"PHASE1","title":"A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2023-03-03","conditions":"Urinary Bladder Neoplasms, Receptors, Fibroblast Growth Factor","enrollment":5},{"nctId":"NCT04666610","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy","status":"ACTIVE_NOT_RECRUITING","sponsor":"UCB Biopharma SRL","startDate":"2021-07-29","conditions":"Childhood Absence Epilepsy, Juvenile Absence Epilepsy","enrollment":153},{"nctId":"NCT06425991","phase":"PHASE1","title":"A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-06-07","conditions":"Relapsed or Refractory Multiple Myeloma","enrollment":108},{"nctId":"NCT03523442","phase":"PHASE1","title":"A Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2018-08-31","conditions":"Prostatic Neoplasms","enrollment":19},{"nctId":"NCT07128524","phase":"PHASE2","title":"Ketones for Opioid Craving","status":"NOT_YET_RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2026-05","conditions":"Opioid Use Disorder","enrollment":50},{"nctId":"NCT02592317","phase":"PHASE1","title":"A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aragon Pharmaceuticals, Inc.","startDate":"2016-02-12","conditions":"Prostatic Neoplasms, Castration-Resistant","enrollment":23},{"nctId":"NCT06550895","phase":"PHASE2","title":"A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-09-16","conditions":"Multiple Myeloma","enrollment":11},{"nctId":"NCT06382948","phase":"PHASE3","title":"Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.","status":"RECRUITING","sponsor":"MedSIR","startDate":"2024-12-05","conditions":"Advanced Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer","enrollment":240},{"nctId":"NCT07466875","phase":"NA","title":"Auricular Stimulation for Nicotine Withdrawal in Psychiatric Inpatients","status":"NOT_YET_RECRUITING","sponsor":"Chiao-Chiao Liao","startDate":"2026-04-01","conditions":"Nicotine Dependence, Nicotine Withdrawal, Tobacco Use Disorder","enrollment":60},{"nctId":"NCT05744375","phase":"PHASE2","title":"Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab","status":"TERMINATED","sponsor":"Spanish Breast Cancer Research Group","startDate":"2023-09-28","conditions":"Locally Advanced Breast Cancer, Metastatic Breast Cancer","enrollment":2},{"nctId":"NCT07467590","phase":"PHASE2","title":"Combination of High and Low-Dose Radiotherapy With Immune Therapy and TKI in Advanced Colorectal Cancer: A Phase II Study","status":"NOT_YET_RECRUITING","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2026-04-01","conditions":"Refractory Colorectal Cancer, Radiotherapy-Induced Immune Priming, Immune Response","enrollment":33},{"nctId":"NCT05884398","phase":"PHASE3","title":"A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2023-08-31","conditions":"Metastatic Castrate-sensitive Prostate Cancer","enrollment":420},{"nctId":"NCT06833515","phase":"NA","title":"The Effect of Using Reciprocal Files Alone and With Different Files on Postoperative Pain","status":"COMPLETED","sponsor":"Harran University","startDate":"2025-03-15","conditions":"Post Operative Pain, Chronic Apical Periodontitis of Pulpal Origin","enrollment":168},{"nctId":"NCT05513001","phase":"PHASE3","title":"An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2022-12-09","conditions":"Chronic Spontaneous Urticaria","enrollment":696},{"nctId":"NCT04179175","phase":"PHASE3","title":"Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2020-03-18","conditions":"Hidradenitis Suppurativa","enrollment":703},{"nctId":"NCT06711887","phase":"PHASE3","title":"Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-05-19","conditions":"Lupus Nephritis","enrollment":315},{"nctId":"NCT05622708","phase":"PHASE4","title":"A Study of Secukinumab to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved Remission","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-03-28","conditions":"Non-radiographic Axial Spondyloarthritis","enrollment":240},{"nctId":"NCT05996471","phase":"PHASE2","title":"A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2023-08-17","conditions":"HIV Infections","enrollment":185},{"nctId":"NCT06504381","phase":"PHASE1, PHASE2","title":"DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2025-01-08","conditions":"High Grade Glioma, MGMT-Unmethylated Glioblastoma, MGMT-Methylated Glioblastoma","enrollment":70},{"nctId":"NCT07347314","phase":"PHASE2","title":"Enfortumab Vedotin in Patients With Advanced Small Bowel Adenocarcinoma Refractory or Intolerant to Platinum-based Combination Therapy","status":"RECRUITING","sponsor":"National Cancer Center, Japan","startDate":"2025-11-04","conditions":"Advanced Small Bowel Adenocarcinoma","enrollment":27}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":384,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Withdrawal of therapy","genericName":"Withdrawal of therapy","companyName":"Royal Brompton & Harefield NHS Foundation Trust","companyId":"royal-brompton-harefield-nhs-foundation-trust","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}